INDICATIONS AND USAGE: RESTASIS
®
and RESTASIS MultiDose
®
ophthalmic emulsion are indicated to increase tear production in
patients whose tear production is presumed to be suppressed due to ocular infl ammation associated with keratoconjunctivitis sicca.
Increased tear production was not seen in patients currently taking topical anti-infl ammatory drugs or using punctal plugs.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: RESTASIS
®
and RESTASIS MultiDose
®
are contraindicated in patients with known or suspected
hypersensitivity to any of the ingredients in the formulation.
WARNINGS AND PRECAUTIONS
POTENTIAL FOR EYE INJURY AND CONTAMINATION: Be careful not to touch the container tip to your eye or other surfaces to
avoid potential for eye injury and contamination.
USE WITH CONTACT LENSES: RESTASIS
®
and RESTASIS MultiDose
®
should not be administered while wearing contact lenses. If
contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes
following administration of RESTASIS
®
and RESTASIS MultiDose
®
ophthalmic emulsion.
ADVERSE REACTIONS: In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion
0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia,
discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
PLEASE SEE NEXT PAGE FOR A BRIEF SUMMARY OF THE FULL PRODUCT INFORMATION.
REFERENCES: 1. RESTASIS
®
(cyclosporine ophthalmic emulsion) 0.05% [prescribing information]. Irvine, CA: Allergan, Inc; 2017. 2. RESTASIS Multidose
®
(cyclosporine
ophthalmic emulsion) 0.05% [prescribing information]. Irvine, CA: Allergan, Inc; 2016. 3. Symphony Health, PHAST Prescription Monthly, data through October 2019. 4. IQVIA,
Xponent PlanTrak, January 2019- October 2019. 5. Managed Markets Insight & Technology, LLC. Yardley, PA: Managed Markets Insight & Technology, LLC; March 2020.
* Increased tear production was seen at 6 months when used as directed.
1,2
†
Source: Managed Markets Insight & Technology, LLC
TM
, a trademark of MMIT Database, as of March 2020. Data are subject to change. Data are not guarantee of coverage, or partial or full payment,
by any payers. Actual benefi ts determined by respective plan administrators, insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage
with applicable insurer. Allergan does not endorse any individual plan. Formular y coverage does not imply effi cacy or safety.
RESTASIS
®
helps more of your
patients make their own real tears.
1,2
*
For patients with decreased tear production
presumed to be due to ocular infl ammation
associated with chronic dry eye
% A ND % OF C OMME R CI A L A ND PA R T D PAT IE N T S A RE C OV E RE D
†
Individual results may var y.
RELY ON THE
EXPERIENCE
#
1
DISPENSED
BRANDED
EYE DROP
7.6 M
PATIENTS
PRESCRIBED
17
YEARS
OF TEARS AND
COUNTING
~
‚
4
© 2020 Allergan. All rights reser ved. All trademarks are the property of their respective owners. RES134940 06/20
